Published on
13:01 GMT
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease
Alcon announced that the FDA has approved acoltremon ophthalmic solution 0.003%, a first-in-class transient receptor potential melastatin 8 (TRPM8) receptor agonist, for the treatment of the signs and symptoms of dry eye disease (DED). The drop, previously …
Source:
Optometry Times
-
Pending
